SML2494

Sigma-Aldrich

Pralatrexate

≥98% (HPLC)

Sinónimos:
PDX, 10-propargyl-10-deazaaminopterin, (2S)-2-[[4-[(1RS)-1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid, N-(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid
Empirical Formula (Hill Notation):
C23H23N7O5
Número de CAS:
Peso molecular:
477.47
MDL number:
En este momento no podemos mostrarle ni los precios ni la disponibilidad

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL

storage temp.

−20°C

SMILES string

O=C([C@@H](NC(C1=CC=C(C(CC(N=C23)=CN=C3N=C(N=C2N)N)CC#C)C=C1)=O)CCC(O)=O)O

InChI

1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1

InChI key

OGSBUKJUDHAQEA-WMCAAGNKSA-N

Biochem/physiol Actions

Pralatrexate is an antifolate that selectively enters cancer cells expressing reduced folate carrier type 1 (RFC-1). Pralatrexate potently inhibits DHFR (dihydrofolate reductase).

pictograms

Health hazard

signalword

Warning

hcodes

WGK Germany

WGK 3

Flash Point F

Not applicable

Flash Point C

Not applicable

Jennifer E Amengual et al.
Blood, 131(4), 397-407 (2017-11-17)
Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies characterized by chemotherapy resistance and poor prognosis. Romidepsin and pralatrexate were approved by the US Food and Drug Administration for patients with relapsed/refractory PTCL, exhibiting response rates of 25% and...
Enrica Marchi et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19(24), 6657-6661 (2013-08-24)
Folates are well known to be essential for many cellular processes, including cellular proliferation. As a consequence, antifolates, the fraudulent mimics of folic acid, have been shown to be potent therapeutic agents in many cancers. Over the past several decades...
Owen A O'Connor et al.
Leukemia & lymphoma, 58(11), 2548-2557 (2017-07-26)
It has been nearly 8 years since pralatrexate became the first drug approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Like most drugs approved for a particular clinical indication...

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.